How big is the Idiopathic Pulmonary Fibrosis Market?

The Idiopathic Pulmonary Fibrosis Market size is expected to reach USD 4.60 billion in 2024 and grow at a CAGR of 6.95% to reach USD 6.43 billion by 2029. Read More

What is the current Idiopathic Pulmonary Fibrosis Market size?

In 2024, the Idiopathic Pulmonary Fibrosis Market size is expected to reach USD 4.60 billion. Read More

Who are the key players in Idiopathic Pulmonary Fibrosis Market?

Cipla Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, FibroGen, Inc. and Horizon Therapeutics plc are the major companies operating in the Idiopathic Pulmonary Fibrosis Market. Read More

Which is the fastest growing region in Idiopathic Pulmonary Fibrosis Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Idiopathic Pulmonary Fibrosis Market?

In 2024, the North America accounts for the largest market share in Idiopathic Pulmonary Fibrosis Market. Read More

What years does this Idiopathic Pulmonary Fibrosis Market cover, and what was the market size in 2023?

In 2023, the Idiopathic Pulmonary Fibrosis Market size was estimated at USD 4.28 billion. The report covers the Idiopathic Pulmonary Fibrosis Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Idiopathic Pulmonary Fibrosis Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Idiopathic Pulmonary Fibrosis Market Share

Statistics for the 2023 & 2024 Idiopathic Pulmonary Fibrosis market share, created by Mordor Intelligence™ Industry Reports. Idiopathic Pulmonary Fibrosis share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Idiopathic Pulmonary Fibrosis Industry

The idiopathic pulmonary fibrosis market is moderately competitive in nature, and there are several local and international companies in this market. Some of the key market players in the market are Afferent Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Cipla Inc., F. Hoffmann-La Roche Ltd, FibroGen, Genentech USA Inc., Jubilant Cadista, Merck & Co. Inc., and Prometic Life Sciences.